A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder

Trial Profile

A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Dasotraline (Primary)
  • Indications Binge-eating disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2018 Primary endpoint of change from baseline in number of binge days in the group treated with dasotraline 4 mg/day versus the placebo-treated group has not been met, according to Sunovion Pharmaceuticals media release.
    • 25 Jul 2018 Primary endpoint of Change from baseline in number of binge days in the group treated with dasotraline 6 mg/day versus the placebo-treated group has been met, according to Sunovion Pharmaceuticals media release.
    • 01 Jul 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top